238 related articles for article (PubMed ID: 27105859)
1. Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.
Hibino S; Nagai T; Yamakawa S; Ito H; Tanaka K; Uemura O
Clin Exp Nephrol; 2017 Feb; 21(1):152-158. PubMed ID: 27105859
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
[TBL] [Abstract][Full Text] [Related]
3. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
[TBL] [Abstract][Full Text] [Related]
4. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome.
Benz MR; Ehren R; Kleinert D; Müller C; Gellermann J; Fehrenbach H; Schmidt H; Weber LT
Ther Drug Monit; 2019 Dec; 41(6):696-702. PubMed ID: 31425441
[TBL] [Abstract][Full Text] [Related]
5. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
[TBL] [Abstract][Full Text] [Related]
7. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
Cortinovis M; Gotti E; Pradini S; Gaspari F; Perico N
Transplantation; 2011 Sep; 92(5):550-6. PubMed ID: 21709602
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
Querfeld U; Weber LT
Pediatr Nephrol; 2018 Dec; 33(12):2253-2265. PubMed ID: 29750317
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
[TBL] [Abstract][Full Text] [Related]
10. Serum albumin level is associated with mycophenolic acid concentration in children with idiopathic nephrotic syndrome.
Nishimura T; Uemura O; Hibino S; Tanaka K; Kitagata R; Yuzawa S; Kasagi T; Fujita N
Eur J Pediatr; 2022 Mar; 181(3):1159-1165. PubMed ID: 34779909
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients.
Filler G; Lepage N; Delisle B; Mai I
Ther Drug Monit; 2001 Oct; 23(5):514-9. PubMed ID: 11591896
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.
Sobiak J; Resztak M; Ostalska-Nowicka D; Zachwieja J; Gąsiorowska K; Piechanowska W; Chrzanowska M
Eur J Pharm Sci; 2015 Sep; 77():189-96. PubMed ID: 26102431
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
[TBL] [Abstract][Full Text] [Related]
14. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
Saint-Marcoux F; Guigonis V; Decramer S; Gandia P; Ranchin B; Parant F; Bessenay L; Libert F; Harambat J; Bouchet S; Broux F; Compagnon P; Marquet P
Pharmacol Res; 2011 May; 63(5):423-31. PubMed ID: 21272643
[TBL] [Abstract][Full Text] [Related]
15. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
16. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol.
Hibino S; Uemura O; Nagai T; Yamakawa S; Iwata N; Ito H; Nakano M; Tanaka K
Pediatr Int; 2015; 57(1):85-91. PubMed ID: 25225083
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.
Filler G; Zimmering M; Mai I
Pediatr Nephrol; 2000 Feb; 14(2):100-4. PubMed ID: 10684356
[TBL] [Abstract][Full Text] [Related]
19. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
[TBL] [Abstract][Full Text] [Related]
20. Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study.
Sobiak J; Resztak M; Pawiński T; Żero P; Ostalska-Nowicka D; Zachwieja J; Chrzanowska M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1249-1259. PubMed ID: 31172249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
